Although the search for pharmacologic inhibitors of telomerase activity represents a promising approach for telomerase-based anti-cancer therapy, the immunological properties of the telomerase reverse transcriptase hTERT suggest that the enzyme is also an attractive target for novel immunotherapies against cancer. Data from both human and murine systems demonstrate that cytotoxic T-lymphocytes (CTL) can recognize peptides derived from TERT and kill TERT-positive tumor cells of multiple histologies. Given the vast overexpression of hTERT in human tumors and its low-level expression in rare normal tissues, clinical trials have begun that test the credentials of hTERT as a broadly applicable target for immunotherapy of cancer.
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Basis of T-lymphocyte immunotherapy
The rationale for exploring hTERT as a potential target for immunotherapy rests ®rmly on experimental ®ndings over the last 10 years that tumor-associated antigens can mediate speci®c anti-cancer T-lymphocyte responses. In pioneering studies dating from the early 1990s, the molecular targets of anti-cancer T-cell responses were characterized by comprehensive analyses of patient derived T-cells (Rosenberg, 1997; Van Pel et al., 1995) . Although this work initially focused on melanoma, it has been subsequently extended to several other malignancies, raising the hypothesis that most, if not all, tumors express antigens that Tlymphocytes can potentially attack (Rosenberg, 1997 (Rosenberg, , 2001 ; Van den Eynde and van der Bruggen, 1997; Van Pel et al., 1995) . This once suspect notion that tumor antigen-speci®c immune responses can lead to tumor regression has now been borne out extensively in animal models (Gilboa, 1999 ) and is being actively tested in human clinical trials. In particular, eorts to develop antigen-speci®c therapeutic vaccination strategies against cancer have greatly accelerated, particularly in light of early reports in melanoma and hematologic malignancies suggesting that vaccination against tumor-associated antigens is safe and potentially eective (Hsu et al., 1996; Nestle et al., 1998; Rosenberg et al., 1998) . To be sure, the promise of therapeutic strategies aimed at these tumor-associated antigens has thus far outweighed clinical results, but knowledge gained from early trials coupled with the impressive development of novel adjuvants and delivery modalities justi®es continued enthusiasm.
Scienti®c attention has chie¯y focused on the CD8 + CTL as the principal eector cell of antigen-speci®c anti-tumor immune responses (Van den Eynde and van der Bruggen, 1997; Van Pel et al., 1995) . Speci®city of the system is ensured by antigen receptors on the surface of CTL which bind to 9 ± 10 amino acid peptides displayed on the surface of tumor cells in the context of major histocompatibility complex (MHC) class I molecules (Figure 1 ). Engagement of the CTL antigen receptor by speci®c peptide/MHC complexes results in a stereotypical T-cell response consisting of cytokine secretion and target lysis. Peptides epitopes recognized by CTL are generated following proteosomal digestion of intracytoplasmic proteins which may or may not be cell surface antigens. Indeed, most tumor antigens discovered thus far are intracytoplasmic self antigens that are either overexpressed or selectively expressed by tumor cells.
Search for universal tumor antigens
Despite the conceptual breakthrough from the discovery of tumor-associated antigens, a major limitation in cancer immunology has been the lack of antigens applicable to a majority of patients with common cancers, i.e. universal tumor-associated antigens. Clinical approaches have generally been tested one malignancy at a time, and in some cases (such as the immunoglobulin idiotypic antigen in B-cell malignancies), patient by patient. To circumvent this obstacle, our group attempted to ®nd universal antigens that could trigger CTL responses against a broad range of tumor types. We used a strategy in which tumor antigens and their CTL epitopes are deduced from genes known to be expressed selectively in tumors. This method of`epitope deduction', beginning with a series of database analyses to select gene products with selective tumor expression and then to scan the deduced protein sequence for peptides that match known MHC binding motifs, has been reviewed elsewhere . It is important to reiterate, however, that the method does not, as its ®rst step, depend on the existence of an innate anti-tumor T-cell response which is then dissected by molecular immunology. Such classical analysis of patient immune responses has failed to identify useful tumor antigens for most common types of cancer, due in large part to the absence or paucity of baseline Tcell responses against these tumors. Candidate antigens identi®ed by epitope deduction must, of course, be validated as therapeutic targets via a series of immunological studies, as described . Antigens must be able to elicit speci®c T-cell responses with the hallmark features of peptide speci®city and MHC restriction, i.e. ideal tumor antigens need to: (i) be expressed by the vast majority of human cancers, (ii) include peptide sequences that bind to MHC molecules, (iii) be processed by tumor cells such that antigen-derived peptides are available for binding to MHC molecules, and (iv) be recognized by the T-cell repertoire in an MHC-restricted fashion, permitting the expansion of naive CTL precursors bearing speci®c T-cell receptors.
Identi®cation of hTERT as a widely expressed tumor-associated antigen
Increasing data suggests that hTERT can serve as a target for widely applicable immunotherapy against cancer. Peptides derived from hTERT are naturally processed by tumor cells, presented in an MHC class Irestricted fashion, and serve as a target for antigenspeci®c CTL (Vonderheide et al., 1999) . Telomerase activity is found in 485% of all human cancers but few normal tissues Shay and Bacchetti, 1997) , and maintains telomeric ends of linear chromosomes and protects them from degradation and end-to-end fusion . As the rate-limiting component of telomerase function, hTERT expression correlates best with telomerase activity (Bodnar et al., 1998; Counter et al., 1998; Harrington et al., 1997; Meyerson et al., 1997; Nakamura et al., 1997; Vaziri and Benchimol, 1998) . Most human cells do not have telomerase activity or hTERT expression Meyerson et al., 1997; Nakamura et al., 1997) . In contrast, the great majority of human tumors exhibit strong telomerase activity , express hTERT (Meyerson et al., 1997; Nakamura et al., 1997; Ramakrishnan et al., 1998) , and maintain the length of their telomeres (Counter et al., 1992 . Expression of telomerase has been directly linked to the development of human cancers (Hahn et al., 1999a) , and its inhibition in telomerase-positive tumors results in tumor death in vitro without the outgrowth of telomerase-negative tumor cells (Hahn et al., 1999b; Herbert et al., 1999; Zhang et al., 1999) . This critical role of telomerase in tumor growth and development suggests that hTERT downregulation as a means of immune escape may itself have deleterious eects on tumor growth. The ®rst immunogenic peptide described from hTERT ± I540 (ILAKFLHWL) ± is found within the middle of the deduced amino acid sequence of hTERT, roughly 70 amino acids to the amino terminus of the ®rst reverse transcriptase motif. The I540 peptide is restricted to the MHC class I allele HLA-A*0201 (HLA-A2), the most frequently expressed HLA allele found among nearly 50% of Caucasians, Asians, and Hispanics and 33% of African-Americans. This peptide was initially deduced from the sequence of hTERT based on computer-assisted analysis of MHC-binding motifs, and was subsequently shown experimently to bind strongly to HLA-A2 (Vonderheide et al., 1999) . CTL were generated from 470% of individuals that were speci®c for the I540 hTERT peptide, and in vitro, these CTL lines killed a wide range of hTERT + tumor cell lines and primary tumors in a peptide-speci®c, MHC-restricted fashion (Figure 2a ). Natural processing and presentation of this peptide was demonstrated by the cytolysis of the HLA-A2 + , telomerase-negative sarcoma cell line U2OS only after retroviral infection with full-length hTERT but not vector alone. Moreover, monoclonal antibodies against HLA-A2 blocked CTL lysis of hTERT-infected U2OS cells (Vonderheide et al., 1999) .
hTERT peptide-speci®c CTL have been further evaluated using tetrameric complexes of MHC class I and peptide in¯ow cytometry. Tetramers built with the I540 hTERT peptide and recombinant HLA-A2 identi®ed a 1 ± 3% population of tetramer + CD8 + cells among ex vivo expanded CTL with a mean Figure 1 Hallmark features of speci®c recognition of Tlymphocytes with their targets. Antigenic peptides from tumorassociated antigens are derived from proteosomal cleavage of intracytoplasmic proteins and are folded together with MHC molecules for presentation on the tumor cell surface. Unique Tcell receptors bind to these peptide/MHC complexes and initiate an immune response culminating in target lysis ¯uorescence index two to three logs above background (Figure 2b ). The level of tetramer staining was predictive of cytotoxicity, and cell sorting experiments showed that cytolytic activity of hTERT-speci®c CTL was contained with the tetramer-positive population (unpublished observations). Since this ®rst report, several other dominant hTERT-derived CTL epitopes have been described, several restricted to other common alleles (Table 1) . For example, the peptide K973 (KLFGVLRLK) binds strongly to HLA-A3 (expressed by 15 ± 25% of patients) and triggers MHC-restricted CTL lysis of hTERT + tumors from a range of histologies . Two hTERT-derived peptides restricted to HLA-A24 have also been identi®ed (Arai et al., 2001) .
Cryptic (as opposed to dominant) hTERT epitopes have also been characterized by the use of heteroclitic peptide analogues, i.e. peptides mutated to increase binding for MHC. In collaboration with K Kosmatopoulos (INSERM, Villejuif, France), a tyrosine substitution at position 1 of two dierent HLA-A2 low anity hTERT wildtype peptides (Table 1) has been found to confer HLA-A2 binding capability and to trigger the ex vivo expansion of peptide-speci®c, tumor-killing CTL. CTL speci®c for either heteroclitic peptide lysed hTERT + multiple myeloma, carcinoma, and melanoma cell lines in an MHC-restricted fashion, suggesting that the wildtype epitopes are naturally processed by tumors (unpublished observations).
Mouse model systems have con®rmed these in vitro observations. Gilboa and colleagues described the induction of anti-murine TERT immunity in mice vaccinated with dendritic cells transduced with murine TERT RNA (Nair et al., 2000) . Following vaccination, mice were partially protected from tumor challenge in three separate tumor models. Given the much broader expression of TERT in mice compared with humans, a higher level of tolerance against TERT might exist in mouse, yet TERT immunity in these studies was easily generated. Interesting from a clinical viewpoint, vaccinated mice in this model remained healthy and did not suer autoimmunity against hematopoietic cells or other murine tissues that express mTERT such as the liver (Nair et al., 2000) .
hTERT-speci®c CTL have been generated ex vivo from cancer patients in multiple experimental systems, suggesting that human T-cells speci®c to hTERT are neither fully deleted nor irreversibly tolerized even in the setting of active neoplasia. In our series, CTL against hTERT were equivalently induced ex vivo from cancer patients and normal volunteers, with CTL from each donor type labeling brightly with peptide/ MHC tetramers and eciently killing hTERT + tumor cells in an MHC-restricted fashion (unpublished observations). In another experimental approach, hTERT-speci®c CTL were generated ex vivo from cancer patients using autologous dendritic cells transduced with hTERT mRNA as the stimulating antigen presenting cell (Nair et al., 2000) . These CTL were shown to lyse primary human tumors in an antigen-speci®c fashion. Finally, Vieweg and colleagues have generated polyclonal anti-tumor CTL ex vivo from patients with prostate or renal cell carcinoma following stimulation with autologous dendritic cells transduced with whole tumor mRNA (Heiser et al., 2001a,b) . These CTL, as designed, had Arai et al. (2001) multiple antigen speci®cities, a signi®cant portion of which was against hTERT (Heiser et al., 2001a,b) .
hTERT immunity vs autoimmunity A major concern of targeting hTERT immunologically is the potential lysis of rare normal cell types in which telomerase has been detected. Telomerase activity is absent in most major organs including heart, lung, liver, kidney, and brain, but activity or hTERT mRNA expression has been reported in hematopoietic stem cells, activated lymphocytes, basal keratinocytes, gonadal cells, and certain epithelial cells (Harle-Bachor and Boukamp, 1996; Kolquist et al., 1998; Norrback and Roos, 1997; Yasumoto et al., 1996) . Activity measurements and evaluations of mRNA expression do not necessarily re¯ect protein levels (Liu et al., 1999 (Liu et al., , 2001 . Certainly, protein expression is one factor aecting peptide/MHC presentation, but given the remarkable nuances of antigen processing, it cannot be reliably assumed that even protein levels of hTERT, if accurately measured, would re¯ect the amount of hTERT presented by tumor MHC. Only now are technologies emerging that can precisely measure peptide/MHC content (Chames et al., 2000; Schirle et al., 2000) , and thus the relationship between peptide presentation and CTL sensitivity remains at best a binary approximation. Therefore, there is as yet no complete explanation for the observation that hTERTspeci®c CTL in vitro do not lyse either telomerasepositive CD34
+ hematopoietic progenitor cells (with or without cytokine stimulation) nor activated T-lymphocytes (Minev et al., 2000; Vonderheide et al., 1999 . It can only be speculated that these ®ndings re¯ect either relatively low levels of hTERT protein, or alternatively, inecient processing hTERT peptide in these normal cells. To be sure, activated B-cells are susceptible to hTERT-speci®c lysis and notably represent the only cells other than tumor cells that to date have been demonstrated to undergo hTERTspeci®c lysis in vitro (Vonderheide et al., 1999) .
Prospect of hTERT as a clinical target for immunotherapy
It is not yet known whether hTERT is a tumor rejection antigen, i.e. a tumor-associated antigen that can elicit an immune response in patients which signi®cantly impacts tumor growth (Gilboa, 1999) . However, if ecient immunity can be successfully elicited in cancer patients without the induction of severe autoimmunity, hTERT clearly becomes a prime candidate for a widely applicable cancer vaccine.
What advantages would hTERT as a tumor antigen have over other characterized antigens? First, the broad expression of hTERT across all types of tumors would enable novel strategies for antigen-speci®c immunotherapy to extend to more patients with common cancers. Given the prevalence of HLA-A2, -A3, and -A24, more than 75% of cancer patients could already be considered for hTERT-speci®c therapies based on the hTERT CTL epitopes currently described (Table 1) .
Second, targeting gene products such as hTERT that are vital to the oncogenic process may help to circumvent the diculties of immune escape. For therapeutic strategies targeting antigens that have no known role in cancer growth, the selection of antigende®cient mutant tumors is a well-recognized limitation (Jager et al., 1996; Thurner et al., 1999; Yee et al., 2000) . In contrast, inhibition of telomerase in telomerase-positive human tumors by genetic methods (Hahn et al., 1999b; Zhang et al., 1999) or through the use of peptide nucleic acid molecules (Herbert et al., 1999) leads to growth arrest. Thus, tumor downregulation of hTERT, as a means of immune escape, might itself be incompatible with sustained tumor growth.
Third, T-cell responses to hTERT may derive from a naõÈ ve repertoire and therefore less likely to be limited by anergy or tolerance as has been described with melanomaassociated antigens (Lee et al., 1999) for which reactivity in patients is usually measurable Valmori et al., 1999) . For hTERT epitopes, cancer patients exhibit no measurable speci®c CTL in uncultured blood; however, hTERT-speci®c CTL from cancer patients can be easily ampli®ed in vitro without evidence of tolerance or functional inactivation (unpublished observations). Of course, a naõÈ ve precursor T-cell frequency to hTERT imposes the need to prime speci®c response in patients, which may be more dicult than boosting ongoing anti-tumor responses against`recall' tumor antigens.
Finally, and probably most importantly, the characterization of universal tumor-associated antigens opens the door to consideration of preventative immunotherapy . Although new candidate antigens need to be tested for safety in a therapeutic clinical setting, it is an important reminder that postexposure vaccination is rarely, if ever, clinically eective. In cancer patients, tumor burden negatively impacts attempts at therapeutic vaccination, and accordingly, there is considerable eort to test strategies that pass phase I safety testing in patients with minimal residual tumor (Simon et al., 2001) . Because hTERT can be predicted to be associated with 485% of human cancers, the opportunity for vaccinating individuals as an immunoprevention strategy can be envisioned for hTERT-based therapies. This opportunity is particularly relevant for healthy individuals considered at high risk for cancer based on genetic factors and medical history. To be sure, any preventative cancer vaccine would require a very narrow toxicity pro®le, and the therapeutic index for hTERT-directed immunotherapies remains to be determined.
hTERT immunotherapy clinical trials
In the United States, at least three phase I clinical trials targeting hTERT in advanced cancer patients are underway, including I540 peptide-based trials at the Dana-Farber Cancer Institute and the National Cancer Institute and a messenger RNA-based trial at Duke University. The primary endpoint of each study is to establish safety of the approach. Unlike pharmacologic agents (e.g. chemotherapy) for which toxicity is often related to dose, here and for other vaccines targeting self antigens, toxicity is a function of the immune response. At the Dana-Farber, seven patients with advanced cancer have been vaccinated with autologous dendritic cells incubated ex vivo with the I540 hTERT peptide and, as an adjuvant, keyhole limpet hemocyanin (KLH). A total of 32 vaccinations have been given with only one grade 2 toxicity (transient fatigue) and no higher grade toxicity. Bone marrow toxicity was not observed. Screening immune assessments demonstrate post-vaccination induction of CD4 + reactivity to KLH and CD8 + reactivity to I540 peptide (unpublished observations). The absence of toxicity despite measurable immune reactivity is encouraging, and opens the door to phase II clinical testing in patients with less advanced disease in whom clinical responses could be expected more reliably.
Summary
Immunological analysis of the telomerase reverse transcriptase hTERT suggests that the enzyme is a potentially important and widely applicable target for anti-cancer T-cell immunotherapy. The ®rst trials aimed at clinically testing this antigen as a tumorrejection antigen have begun. If immunity against hTERT can be generated safely and eectively in humans, the possibility of broad spectrum immunotherapy or even immunoprevention therapy based on this and similar antigens could be considered.
